A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D

Exclusion criteria

• ✕. History of current or past decompensated liver diseases (including coagulopathy, hepatic encephalopathy, and variceal bleeding);
• ✕. Comorbidity of underlying diseases such as severe infection, heart failure and chronic obstructive pulmonary disease, and other severe diseases;
• ✕. Diabetes mellitus and hypertension not effectively controlled (systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 100 mmHg);
• ✕. Current or previous uncontrolled epilepsy or psychiatric disorders;
• ✕. History of solid organ transplantation;
• ✕. Evidence of active or suspected malignancies or history of malignancies, or untreated premalignant lesions within the past 5 years (except for successfully treated cervical carcinoma in situ at least 1 year before screening, and successfully treated basal cell carcinoma and squamous cell carcinoma \[≤ 3 cases of resected skin cancer within 5 years before screening \]), or history of liver cancer;
• ✕. History of alcohol abuse or drug addiction at present or within 6 months prior to participation in this study; 6. Subjects co-infected with hepatitis A, C, or E virus or with uncontrolled HIV co-infection (those with positive HCV antibody but negative HCV RNA at screening are eligible for enrollment. HIV-infected patients may be enrolled if cluster of differentiation 4 (CD4) cell count is \> 500/mL and HIV RNA is below the limit of detection for at least 12 months);